(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.
The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said.
Reuters could not immediately confirm the FT report.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)
Comments